MARQIBO adverse reactions

Most commonly reported (>5%) Grade 3 or greater adverse reactions among 83 patients receiving the clinical
dosing regimen1*

* National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0.
Study 2 was a phase 1 study that included 18 patients treated at the MARQIBO recommended dose of 2.25 mg/m2 intravenously over 1 hour every 7 days.
Including neuropathy-associated adverse events.

  • Adverse reactions were observed in 100% of patients
  • Dose reduction, delay, or omission occurred in 53% of patients during the treatment
  • Adverse reactions related to neuropathy and leading to treatment discontinuation were decreased vibratory sense, facial palsy, hyporeflexia, constipation, asthenia, fatigue, and musculoskeletal pain, each reported in at least one patient

For more information about the safety profile for MARQIBO, click here to download the full Prescribing Information.

Select Important Safety Information

  • The most commonly reported adverse reactions (incidence >30%) in clinical studies include constipation (57%), nausea (52%), pyrexia (43%), fatigue (41%), peripheral neuropathy (39%), febrile neutropenia (38%), diarrhea (37%), anemia (34%), decreased appetite (33%), and insomnia (32%)
  • A total of 75.9% of patients experienced serious adverse events (SAEs) during the studies. The most commonly reported SAEs included febrile neutropenia (20.5%), pyrexia (13.3%), hypotension (7.2%), respiratory distress (6.0%), and cardiac arrest (6.0%)